Novartis Investigative Site

Afula 1834111

0 studies enrolling now · 14 studies all time

What they study most

Behcet Disease, Chronic Plaque Type Psoriasis, Chronic Plaque-type Psoriasis, Chronic Severe Plaque-type Psoriasis, Chronic Spontaneous Urticaria, Leukaemia, Lymphocytic, Chronic, Leukemia, Myelomonocytic, Chronic, Moderate to Severe Palmoplantar Psoriasis, Moderate to Severe Plaque-type Psoriasis, Myelodysplastic Syndromes, Plaque-type Psoriasis, Prostatic Cancer, Castration-Resistant

Studies at this site

• A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) — Running, not enrolling
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia — Completed
• A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. — Completed
• Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis — Completed
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year — Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis — Completed
• AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis — Completed
• Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis — Completed
• Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis — Stopped early
• Phase III Study in Refractory Behcet's Disease — Completed
• AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis — Completed